-
Mashup Score: 0Monthly Oncology Tumor Boards: Updates in Treatment of Hairy Cell Leukemia | NCCN Continuing Education - 3 day(s) ago
Learn about the recent advances as well as the challenges involved in the diagnosis and management of classical hairy cell leukemia (HCL) and HCL-variant.
Source: education.nccn.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 7NCCN 2024 Oncology Fellows Program: New Horizons in Quality Cancer Care | NCCN Continuing Education - 1 month(s) ago
Designed specifically for oncology fellows, this half-day, CE-certified program seeks to educate future oncology practitioners about the application of the NCCN Guidelines, the importance of communicating with patients and caregivers about difficult and sensitive topics, and preparing for entry into the oncology workforce.
Source: education.nccn.orgCategories: General Medicine News, Onc News and JournalsTweet-
During today's NCCN 2024 Oncology Fellows Program attendees learned the importance of communicating with patients and caregivers about sensitive topics, and preparing for entry into the oncology workforce. Learn more: https://t.co/RVM02yAIt8 #NCCN2024 https://t.co/KhBo2HfgmF
-
-
Mashup Score: 2Behind the Guidelines: Insights into the Standard of Care in Oncology 2024 (NCCN Guidelines® Insights 2024) | NCCN Continuing Education - 2 month(s) ago
Understand how and why important decisions are made in the development of the NCCN Guidelines and apply this information to clinical decision pathways in oncology.
Source: education.nccn.orgCategories: General Medicine News, Onc News and JournalsTweet-
Earn credit online while learning about important NCCN Guidelines updates. Learn more: https://t.co/QXaWNDjBWS https://t.co/JWse3IHUHi
-
-
Mashup Score: 57
By working through a series of realistic case scenarios, you will experience how to manage a variety of AML presentations over time. As you make decisions, you will receive expert corrective mentoring from virtual colleagues to help you recognize optimal decision-making patterns.
Source: education.nccn.orgCategories: General Medicine News, Hem/OncsTweet-
Check out this really cool #AML interactive Simulator Project that myself and @jaltmanmd helped @NCCN develop. It's good for CME credit and pretty fun! AI meets AML... https://t.co/ObUq7xP2ZZ
-
-
Mashup Score: 1Recorded Presentations from the NCCN 2023 Annual Congress: Hematologic Malignancies™ | NCCN Continuing Education - 4 month(s) ago
NCCN Continuing Education Disclosure PolicyIt is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that…
Source: education.nccn.orgCategories: General Medicine News, Onc News and JournalsTweet-
Recordings from the 2023 Annual Congress are available! Access 20 recorded presentations to learn the latest advances in hematologic malignancies and earn CE credits! Learn more: https://t.co/H7ddoTCxnw https://t.co/aD8PQ4sElk
-
-
Mashup Score: 0Monthly Oncology Tumor Boards: Management of Advanced Ovarian Cancer | NCCN Continuing Education - 6 month(s) ago
Due to the rapidly changing treatment landscape, clinicians in the community who treat advanced ovarian cancer may not be aware of new data. In order to optimize clinical outcomes, it is crucial for clinicians to be educated on this topic to ensure that they select the most appropriate treatment options for their patients with ovarian cancer.
Source: education.nccn.orgCategories: General Medicine News, Onc News and JournalsTweet-
Join us for the upcoming Oncology Tumor Board Webinar on December 6 focusing on the management of advanced ovarian cancer. Speakers include Deborah K. Armstrong, MD, and Carol D. Riley, RN, MSN, CRNP, from @hopkinskimmel. Register now: https://t.co/fb6XTSPbhM https://t.co/tDiFOIoTYT
-
-
Mashup Score: 3
By working through a series of realistic case scenarios, you will experience how to manage a variety of AML presentations over time. As you make decisions, you will receive expert corrective mentoring from virtual colleagues to help you recognize optimal decision-making patterns.
Source: education.nccn.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The Acute Myeloid Leukemia Patient Management Simulator is now online! Complete realistic case scenarios to assess treatment options and receive expert mentoring to improve care for patients with AML. Access now and earn CE: https://t.co/mE9l0d6pBg https://t.co/fVvvLcUQ8L
-
-
Mashup Score: 2
By working through a series of realistic case scenarios, you will experience how to manage a variety of AML presentations over time. As you make decisions, you will receive expert corrective mentoring from virtual colleagues to help you recognize optimal decision-making patterns.
Source: education.nccn.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Check out this really cool #AML interactive Simulator Project that myself and @jaltmanmd helped @NCCN develop. It's good for CME credit and pretty fun! AI meets AML... https://t.co/ObUq7xP2ZZ
-
-
Mashup Score: 0Monthly Oncology Tumor Boards: Management of Differentiated and Medullary Thyroid Carcinomas | NCCN Continuing Education - 8 month(s) ago
Differentiated thyroid cancers have an excellent prognosis with appropriate treatment, and education in optimal management will help guide treatment decisions. For cases of thyroid cancer that require more aggressive treatment, knowledge of the most current treatment approaches can help clinicians give their patients a chance at the best possible outcome.
Source: education.nccn.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join us on September 25 for the upcoming Tumor Board webinar focusing on Management of Thyroid Carcinomas. Speakers include Giuseppe Barbesino, MD; Carrie Cunningham, MD, MPH; and Lori J. Wirth, MD from @MGHCancerCenter. Register now: https://t.co/bGmgcLQ7GQ https://t.co/jyotJuJy9N
-
-
Mashup Score: 1
As the clinical understanding of biomarkers in colorectal cancer has deepened, it has become increasingly clear that deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H) colorectal cancer should be treated differently from proficient mismatch repair or microsatellite stable (pMMR/MSS) disease in order to reach the best possible outcomes for patients.
Source: education.nccn.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Join us on August 14 for the Oncology Tumor Board webinar focusing on the treatment of deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H) colorectal cancer. Speakers are from @UWCarbone. Register now: https://t.co/Vpxbfwv3Br https://t.co/2DSoLEAu1O
-
Join us for the upcoming Tumor Board webinar on May 22 focusing on Updates in Treatment of Hairy Cell Leukemia. Speakers include Brian T. Hill, MD, PhD; Joslyn Rudoni, PharmD, BCOP; and Allison Winter, MD from @ClevelandClinic. Register now: https://t.co/O43oUJEy7I https://t.co/aNeO96Afpl